Only significant change that I see is that each dose cohort previously was 3 patients and is now 3-6 patients. That has the potential to speed up the trial a bit.
They also loosened up the definition of the MTD - that is good, because a single patient can always have a somewhat idiosyncratic reaction.
Market Data 
Markets 
AI
